Half of Ovarian Cancer Patients Respond to Quisinostat Combo Therapy, Phase 2 Clinical Trial Shows

Half of Ovarian Cancer Patients Respond to Quisinostat Combo Therapy, Phase 2 Clinical Trial Shows
Half of patients with advanced ovarian cancer responded either fully or partially to a combination of quisinostat, Taxol (paclitaxel) and Paraplatin (carboplatin), according to a Phase 2 clinical trial. The trial (NCT02948075) dealt with patients with metastatic or advanced ovarian cancer whose cancer had progressed after first-line platinum and Taxol-based chemotherapy. The regression rate of a little more than half the patients who received the combo was much higher than researchers expected. Quisinostat's maker, NewVac, presented the results at the annual meeting of the American Society of Clinicial Oncology in Chicago, June 2-6. The poster-session presentation was titled “A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC).” Quisinostat inhibits a protein called histone deacetylase, or HDAC1, which helps regulate gene expression in cells. Expression is the process by which information from a gene is used to create a functional product like a protein. By blocking HDAC1, quisinostat lowers production of the E-cadherin protein. That, in turn, decreases mechanisms associated with ovarian cancer's resistance to platinum chemotherapies. The trial was designed to investigate the safety and effectiveness of quisinostat, combined with Taxol and Paraplatin, in 31 patien
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *